Exploramed: Incubators the Second Time Around

Ten years ago, when Josh Makower, MD, started an incubator, ExploraMed Inc., it was arguably the device industry's first. Makower proposed a different model for device company creation: to begin without a clear idea of the business, but, backed by some money and a vision of the clinical need, to search for the right technology to address that need. Now, a year after selling one of the incubator's start-ups, TransVascular, to Medtronic, Makower has resurrected ExploraMed, and he's just funded his first company. While the model remains largely the same, subtle differences between ExploraMed I and ExploraMed II highlight how much the medical device start-up world has changed over the past decade.

Ten years ago, Josh Makower, MD, started an incubator, ExploraMed Inc. , arguably the device industry's first, at a time when few people in the medical device industry felt there was any need for incubators. After all, device company creation was roaring ahead, backed by an eager venture capital community just discovering medical technology and a public investor market that was eagerly embracing the promise implicit in the products that device companies offered.

Over the next several years, however, ExploraMed and the device start-up community went in somewhat separate directions. While the incubator...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Milner Pitch Day: Multiomic Pathology, Microcancer Avatars And Cell Morphology Intelligence

 

The Milner Institute, the on-campus hub for start-up acceleration at Cambridge University, hosted its annual Pitch Day on July 1. Start-ups Panakeia, PathwayBio and Sentinal4D presented diagnostic technologies.

‘Be Quick, But Don’t Hurry’: Dexcom CEO Talks CGM Market Success

 
• By 

Dexcom’s CEO Kevin Sayer discusses this fall’s planned launch of the 15-day G7 CGM, downplays Abbott’s dual-sensor while focusing on development of multi-analyte G8, making OTC Stelo app more “consumerish” for Europeans, and more.

Medtronic’s ‘Strategic Expansion’ Into Remote Monitoring

 

“The Corsano wearable strengthens Medtronic’s acute care and monitoring portfolio,” Marc De Martini, vice president at Medtronic, told Medtech Insight.

UK Center To Develop Brain Stimulation Devices Opens

 

Backed by £50m of UK government funding, the new research center will delve into neural dynamics to develop novel devices ranging from brain implants to wearables.

More from Business

‘Be Quick, But Don’t Hurry’: Dexcom CEO Talks CGM Market Success

 
• By 

Dexcom’s CEO Kevin Sayer discusses this fall’s planned launch of the 15-day G7 CGM, downplays Abbott’s dual-sensor while focusing on development of multi-analyte G8, making OTC Stelo app more “consumerish” for Europeans, and more.

Medtronic’s ‘Strategic Expansion’ Into Remote Monitoring

 

“The Corsano wearable strengthens Medtronic’s acute care and monitoring portfolio,” Marc De Martini, vice president at Medtronic, told Medtech Insight.

European Commission Asks For ‘Open Minds’ On Unified Drug/Device Research Pathway

 
• By 

As the EU tests the feasibility of a radical “all-in-one” procedure for combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.